Compare ARVN & RWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | RWT |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 574.0M |
| IPO Year | 2018 | 1996 |
| Metric | ARVN | RWT |
|---|---|---|
| Price | $9.20 | $4.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | ★ $15.05 | $6.82 |
| AVG Volume (30 Days) | 878.8K | ★ 1.9M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 12.83% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $26.59 |
| Revenue Next Year | N/A | $22.21 |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.96 | $4.19 |
| 52 Week High | $14.22 | $6.97 |
| Indicator | ARVN | RWT |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 52.63 |
| Support Level | $7.90 | $4.44 |
| Resistance Level | $9.65 | $4.97 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 75.50 | 97.37 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.